Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 6 for:    ONCOS-102

A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02963831
Recruitment Status : Recruiting
First Posted : November 15, 2016
Last Update Posted : August 26, 2019
Sponsor:
Collaborators:
Cancer Research Institute, New York City
MedImmune LLC
Targovax ASA
Information provided by (Responsible Party):
Ludwig Institute for Cancer Research

Brief Summary:
This is a two-part Phase 1/2 dose escalation and dose expansion study of the GMCSF-encoding adenovirus, ONCOS-102, in combination with anti-programmed death ligand-1 (PDL1) antibody, durvalumab, in adult subjects with peritoneal disease who have failed prior standard chemotherapy and have histologically confirmed platinum-resistant or refractory epithelial ovarian cancer or colorectal cancer.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Platinum-resistant Ovarian Cancer Appendiceal Cancer Biological: ONCOS-102 Drug: Durvalumab Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 78 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Dose Escalation Study With Expansion Cohorts to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
Actual Study Start Date : September 7, 2017
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : October 2022


Arm Intervention/treatment
Experimental: Dose Escalation

During Phase 1 of the study, subjects will be evaluated for DLTs before proceeding to a subsequent cohort. Dose escalation for the determination of RCD will be performed based on the available dose levels and the respective rules for a standard 3 + 3 dose escalation study design.

For Cohort A, ONCOS-102 will be given as monotherapy the first six weeks, and then durvalumab (1500 mg) will be starting on day 71.

For Cohorts B and C, ONCOS-102 will be administered for a total of 6 weeks while durvalumab will be given for a total of 12 four-week cycles.

Biological: ONCOS-102
ONCOS-102 will be administered intraperitoneally infusion at weekly intervals for 6 weeks.

Drug: Durvalumab
Durvalumab will be administered by IV infusion once every four weeks for a total of 12 four-week cycles.
Other Name: MEDI4736

Experimental: Cohort 1: Platinum-resistant epithelial ovarian cancer
ONCOS-102 will be administered for a total of 6 weeks, while durvalumab will be administered for a total of 12 cycles, starting on Day 15.
Biological: ONCOS-102
ONCOS-102 will be administered intraperitoneally infusion at weekly intervals for 6 weeks.

Drug: Durvalumab
Durvalumab will be administered by IV infusion once every four weeks for a total of 12 four-week cycles.
Other Name: MEDI4736

Experimental: Cohort 2: Colorectal cancer
ONCOS-102 will be administered for a total of 6 weeks, while durvalumab will be administered for a total of 12 cycles, starting on Day 15.
Biological: ONCOS-102
ONCOS-102 will be administered intraperitoneally infusion at weekly intervals for 6 weeks.

Drug: Durvalumab
Durvalumab will be administered by IV infusion once every four weeks for a total of 12 four-week cycles.
Other Name: MEDI4736




Primary Outcome Measures :
  1. Number of Adverse Events [ Time Frame: up to 15 months ]
    Clinical laboratory tests, vital sign and weight measurements, physical exams, performance status evaluation, imaging scans and any other medically indicated assessments, including subject interviews, will be performed to detect new abnormalities and deteriorations of any pre-existing conditions. The investigator will evaluate any laboratory abnormalities for clinical significance, and clinically significant abnormalities will be recorded as adverse events. All clinically significant abnormalities and deteriorations from time of signing the informed consent to the end of study visit will be recorded in the Case Report Forms as adverse events and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.


Secondary Outcome Measures :
  1. Clinical Benefit (Complete Response, Partial Response and Stable Disease) [ Time Frame: up to 24 weeks ]
    Clinical Benefit is defined as percentage of subjects who are in the study and not in progression at the end of Week 24.

  2. Objective Response Rate [ Time Frame: up to 15 months ]
  3. Progression-free survival [ Time Frame: Up to 15 months ]
  4. Overall Survival [ Time Frame: up to 4 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects with peritoneal disease who have failed prior standard chemotherapy and have histologic confirmation of epithelial ovarian cancer or metastatic colorectal cancer (CRC) including cancer originating from the appendix.
  2. Subject is willing to undergo a core needle biopsy during screening and Cycle 2, Study Week 5. Archival tumor samples are requested, but are not required for eligibility.
  3. Previously treated for advanced cancer with no additional therapy options available known to prolong survival.
  4. Laboratory parameters for vital functions should be in the normal range or not clinically significant.
  5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

Exclusion Criteria:

  1. Treatment with an investigational agent within 4 weeks of starting study treatment or prior treatment with a checkpoint inhibitor (cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) antibodies).
  2. Subject has known active central nervous system metastasis, glioma and nervous system malignancies including carcinomatous meningitis. Subjects with asymptomatic brain metastases or spinal cord compression who have been treated, are considered stable, and who have not received corticosteroids or anticonvulsants for at least 28 days prior to screening may be included. Subject has other active malignancy.
  3. Known immunodeficiency or known to have evidence of acute or chronic or human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C or other uncontrolled inter-current illnesses.
  4. Ongoing bowel perforation or presence of bowel fistula or abscess or history of small or large bowel obstruction within 3 months of registration, including subjects with palliative gastric drainage catheters. Subjects with palliative diverting ileostomy or colostomy are allowed if they have been symptom-free for more than 3 months.
  5. Subjects with clinically significant cardiovascular disease, history of organ transplant or allogeneic bone marrow transplant, active known or history of autoimmune disease that might recur or major surgery within 28 days prior to the first dose or still recovering from prior surgery.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02963831


Contacts
Layout table for location contacts
Contact: Mary Macri 212-450-1515 clintrialinformation@licr.org

Locations
Layout table for location information
United States, Florida
Research Facility Recruiting
Miami, Florida, United States, 33136
United States, New York
Research Facility Recruiting
Buffalo, New York, United States, 14263
Research Facility Recruiting
New York, New York, United States, 10065
United States, Ohio
Research Facility Recruiting
Toledo, Ohio, United States, 43614
United States, Virginia
Research Facility Recruiting
Charlottesville, Virginia, United States, 22903
Sponsors and Collaborators
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City
MedImmune LLC
Targovax ASA

Layout table for additonal information
Responsible Party: Ludwig Institute for Cancer Research
ClinicalTrials.gov Identifier: NCT02963831     History of Changes
Other Study ID Numbers: LUD2015-008
First Posted: November 15, 2016    Key Record Dates
Last Update Posted: August 26, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ludwig Institute for Cancer Research:
Oncos-102
Durvalumab
Peritoneal
Cyclophosphamide
Additional relevant MeSH terms:
Layout table for MeSH terms
Appendiceal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Cecal Neoplasms
Cecal Diseases
Durvalumab
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs